Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 3,300 shares of the stock in a transaction dated Wednesday, September 12th. The shares were sold at an average price of $351.66, for a total transaction of $1,160,478.00. Following the sale, the director now directly owns 392,204 shares of the company’s stock, valued at $137,922,458.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Illumina stock traded down $2.79 during midday trading on Friday, hitting $353.12. The company had a trading volume of 551,245 shares, compared to its average volume of 838,354. The firm has a market capitalization of $51.42 billion, a P/E ratio of 88.28, a PEG ratio of 2.90 and a beta of 0.97. The company has a quick ratio of 2.44, a current ratio of 2.74 and a debt-to-equity ratio of 0.22. Illumina, Inc. has a 12-month low of $196.00 and a 12-month high of $357.93.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, July 30th. The life sciences company reported $1.43 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.11 by $0.32. The firm had revenue of $830.00 million during the quarter, compared to analyst estimates of $786.88 million. Illumina had a net margin of 20.88% and a return on equity of 26.64%. Illumina’s revenue was up 25.4% on a year-over-year basis. During the same period last year, the firm posted $0.82 EPS. research analysts anticipate that Illumina, Inc. will post 5.46 earnings per share for the current fiscal year.
ILMN has been the subject of several analyst reports. Canaccord Genuity reissued a “buy” rating and set a $340.00 price target (up from $330.00) on shares of Illumina in a research report on Friday, July 27th. Deutsche Bank increased their price target on shares of Illumina from $280.00 to $330.00 and gave the company a “buy” rating in a research report on Tuesday, July 31st. BidaskClub raised shares of Illumina from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 1st. Citigroup increased their price target on shares of Illumina from $275.00 to $330.00 and gave the company a “buy” rating in a research report on Monday, June 25th. Finally, Morgan Stanley raised shares of Illumina from an “underweight” rating to an “equal weight” rating and increased their price target for the company from $210.00 to $320.00 in a research report on Tuesday, August 7th. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $308.25.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Recommended Story: Closed-End Mutual Funds (CEFs)
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.